<div dir="ltr"><div class="gmail_quote"><div dir="ltr"><div style="font-family:arial,helvetica,sans-serif;font-size:small"><h1 align="center" style="text-align:center;text-indent:0in;break-after:avoid;font-size:12pt;font-family:"Times New Roman",serif"><span style="font-size:14pt;text-indent:0in"><span class="gmail_default" style="font-family:arial,helvetica,sans-serif;font-size:small"></span>BIOINFORMATICS POSTDOC
POSITION FOR EPIGENOMICS</span><br></h1>
<p class="MsoNormal" style="text-align:justify;font-size:12pt;font-family:"Times New Roman",serif"><b><u><span lang="FR-BE">Job description</span></u></b><b><span lang="FR-BE">: </span></b><span lang="FR-BE"></span></p>
<p class="MsoNormal" style="text-align:justify;font-size:12pt;font-family:"Times New Roman",serif"><span lang="EN-US">A <b>postdoctoral </b>position is available for a highly motivated researcher that wishes to join the
Laboratory of Cancer Epigenetics headed by <b>Prof.
François Fuks</b> (ULB-Cancer Research Center, Brussels). The research goal
will be the analysis of transcriptomic and epigenomic changes (<i>e.g.</i> DNA methylation) that arise in
cancers. Our major focus is particularly on the analysis of next generation
sequencing data concerning a novel RNA epigenetic modification, which our lab
recently investigated,<b> </b>will be one
of the main challenging tasks of the candidate (Delatte et al.,<b> <i>Science</i>
2016</b>). He/she will participate in several projects with high impact publication
potentials.</span></p>
<p class="MsoNormal" style="text-align:justify;font-size:12pt;font-family:"Times New Roman",serif"><span lang="EN-US" style="font-size:6pt"> </span></p>
<p class="MsoNormal" style="text-align:justify;font-size:12pt;font-family:"Times New Roman",serif"><b><u><span lang="EN-US">Working environment:</span></u></b></p>
<p class="MsoNormal" style="text-align:justify;font-size:12pt;font-family:"Times New Roman",serif"><span lang="EN-US">The candidate will have the possibility
to analyse many types of sequencing methods (RNA-seq, ChIP-seq, RIP-seq,
CLIP-seq, Oxford Nanopore, …), while having a direct interaction with </span><span lang="EN-US" style="color:rgb(38,38,38)">the wet lab biologists generating the data</span><span lang="EN-US">. The host lab is part of the ULB-Cancer
Research Center (U-CRC) (</span><a href="http://ucrc.ulb.be/" style="color:blue" target="_blank"><span lang="EN-US">http://ucrc.ulb.be/</span></a><span lang="EN-US">), providing opportunity to interact with high
profile scientific community. The candidate will <b>join other </b></span><b><span lang="EN-US" style="color:rgb(38,38,38)">experienced bioinformaticians</span></b><span lang="EN-US" style="color:rgb(38,38,38)"> working on transcriptomics and epigenomics</span><span lang="EN-US">. The lab has collaborations in
Belgium and abroad, while being international, the working language is English.</span></p>
<p class="MsoNormal" style="text-align:justify;font-size:12pt;font-family:"Times New Roman",serif"><b><u><span lang="EN-US" style="font-size:6pt"><span style="text-decoration-line:none"> </span></span></u></b></p>
<p class="MsoNormal" style="text-align:justify;font-size:12pt;font-family:"Times New Roman",serif"><b><u><span lang="EN-US">Profile:</span></u></b></p>
<p class="MsoNormal" style="text-align:justify;font-size:12pt;font-family:"Times New Roman",serif"><span lang="EN-US">The candidate should hold a PhD (or submitted)
in bioinformatics, computational biology, bio-engineering or computer sciences.
He/She should demonstrate proficiency in statistics and programming with R, Python,
and/or Bash. Pipeline development and automation will be a plus. Experience with
next-generation sequencing (esp. RNA-seq, ChIP-seq) and clinical data will be
assets. The applicant should have good organizational skills, a taste for
interdisciplinary research, excellent scientific writing and presenting skills
and abilty to work independently and with team. The interaction with the
biologists in the lab will be key and genuine interest for biology and clinical
researches is required. This position is <b>funded for 2 years</b>, with the
possibility of further renewal. Screening of applications begins immediately
and continues until an outstanding candidate is selected (<b>f</b></span><b><span lang="EN-US" style="color:rgb(41,41,41)">lexible
starting date</span></b><span lang="EN-US" style="color:rgb(41,41,41)">)</span><span lang="EN-US">.</span></p>
<p class="MsoNormal" style="text-align:justify;font-size:12pt;font-family:"Times New Roman",serif"><span lang="EN-US" style="font-size:6pt"> </span></p>
<p class="MsoNormal" style="text-align:justify;font-size:12pt;font-family:"Times New Roman",serif"><b><u><span lang="EN-US">How to apply?</span></u></b></p>
<p class="MsoNormal" style="text-align:justify;font-size:12pt;font-family:"Times New Roman",serif"><span lang="EN-US">Informal
enquiries, a motivation letter, a CV and names of two referees should be sent
to: Gaurav DUBE</span> (Gaurav.Dube<span lang="EN-US">@<a href="http://ulb.ac.be" target="_blank">ulb.ac.be</a></span><span lang="EN-US">)</span></p>
<p class="MsoNormal" style="font-size:12pt;font-family:"Times New Roman",serif"><span style="color:black">Lab
website: </span><a href="http://fukslab.ulb.be/" style="color:blue" target="_blank"><i>http://fukslab.ulb.be/</i></a><b><u><span style="font-size:6pt;color:black"></span></u></b></p>
<p class="MsoNormal" style="text-align:justify;font-size:12pt;font-family:"Times New Roman",serif"><a name="m_-4240881639107585028_OLE_LINK4"></a><a name="m_-4240881639107585028_OLE_LINK3"><b><u><span style="font-size:6pt;color:black"><span style="text-decoration-line:none"> </span></span></u></b></a></p>
<p class="MsoNormal" style="text-align:justify;font-size:12pt;font-family:"Times New Roman",serif"><b><u><span lang="EN-US">Selected publications:</span></u></b></p>
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse">
<tbody><tr style="height:2.85pt">
<td width="319" valign="top" style="width:239.3pt;padding:0in 5.4pt;height:2.85pt">
<p class="MsoNormal" style="text-align:justify;font-size:12pt;font-family:"Times New Roman",serif"><span lang="FR-BE">- Bonvin et al., <b><i>Cancer
Res.</i></b> 2019</span></p>
<p class="MsoNormal" style="text-align:justify;font-size:12pt;font-family:"Times New Roman",serif"><span lang="FR-BE">- Collignon et al., <b><i>Science
Adv.</i></b> 2018</span></p>
<p class="MsoNormal" style="text-align:justify;font-size:12pt;font-family:"Times New Roman",serif"><span lang="FR-BE">- Jeschke*, Bizet* et al., <b><i>J.
Clin. Invest.</i></b> 2017</span></p>
<p class="MsoNormal" style="text-align:justify;font-size:12pt;font-family:"Times New Roman",serif"><span lang="FR-BE">- Van Grembergen et al., <b><i>Science
Adv.</i></b> 2016</span></p>
<p class="MsoNormal" style="text-align:justify;font-size:12pt;font-family:"Times New Roman",serif"><span lang="FR-BE">- Delatte et al. <b><i>Science</i></b>
2016</span></p>
<p class="MsoNormal" style="text-align:justify;font-size:12pt;font-family:"Times New Roman",serif"><span lang="FR-BE">- Boumahdi et al. <b><i>Nature</i></b>
2014</span></p>
<p class="MsoNormal" style="text-align:justify;font-size:12pt;font-family:"Times New Roman",serif"><span lang="FR-BE">- Deplus et al. <b><i>Cell
Rep</i></b>. 2014</span></p>
<p class="MsoNormal" style="text-align:justify;font-size:12pt;font-family:"Times New Roman",serif"><span lang="EN-US">- Dedeurwaerder*,<sup> </sup>Defrance*
et al.</span></p>
<p class="MsoNormal" style="text-align:justify;font-size:12pt;font-family:"Times New Roman",serif"><b><i><span lang="EN-US">
Briefings in Bioinformatics</span></i></b><i><span lang="EN-US"> </span></i><span lang="EN-US">2014</span></p>
</td>
<td width="331" valign="top" style="width:248.1pt;padding:0in 5.4pt;height:2.85pt">
<p class="MsoNormal" style="text-align:justify;font-size:12pt;font-family:"Times New Roman",serif"><span lang="FR-BE">- Delatte et al. <b><i>EMBO
J.</i></b><i> </i>2014</span></p>
<p class="MsoNormal" style="text-align:justify;font-size:12pt;font-family:"Times New Roman",serif"><span lang="FR-BE">- Deplus et al. <b><i>EMBO
J.</i></b> 2013</span></p>
<p class="MsoNormal" style="text-align:justify;font-size:12pt;font-family:"Times New Roman",serif"><span lang="FR-BE">- Volkmar et al. <b><i>EMBO
J.</i></b> 2012</span></p>
<p class="MsoNormal" style="text-align:justify;font-size:12pt;font-family:"Times New Roman",serif"><span lang="FR-BE">- Dedeurwaerder et al. <b><i>EMBO
Mol Med.</i></b>2011</span></p>
<p class="MsoNormal" style="text-align:justify;font-size:12pt;font-family:"Times New Roman",serif"><span lang="FR-BE">- Dedeurwaerder*,<sup> </sup>Defrance*
et al. </span></p>
<p class="MsoNormal" style="text-align:justify;font-size:12pt;font-family:"Times New Roman",serif"><b><i><span lang="FR-BE">
Epigenomics</span></i></b><i><span lang="FR-BE"> </span></i><span lang="FR-BE">2011</span></p>
<p class="MsoNormal" style="text-align:justify;font-size:12pt;font-family:"Times New Roman",serif"><span lang="FR-BE">- Fuks F. <b><i>Nature</i></b><i> </i>2010</span></p>
<p class="MsoNormal" style="text-align:justify;font-size:12pt;font-family:"Times New Roman",serif"><span lang="FR-BE">- Villa et al. <b><i>Cancer
Cell</i></b><i> </i>2007</span></p>
<p class="MsoNormal" style="text-align:justify;font-size:12pt;font-family:"Times New Roman",serif"><span lang="FR-BE">- Viré et al. </span><b><i><span lang="EN-US">Nature</span></i></b><span lang="EN-US"> 2006</span></p>
</td>
</tr>
</tbody></table><br></div><div style="font-family:arial,helvetica,sans-serif;font-size:small">---</div><div style="font-family:arial,helvetica,sans-serif;font-size:small">Gaurav DUBE</div><div><div dir="ltr" data-smartmail="gmail_signature"><div dir="ltr"><div><div dir="ltr">Laboratory of Cancer Epigenetics<br>ULB-Cancer Research Centre (U-CRC)<br>University of Brussels (U.L.B)<br>Faculty of Medicine<br>1070 Brussels, Belgium<br><br><a href="mailto:gaurav.dube@ulb.ac.be" target="_blank">gaurav.dube@ulb.ac.be</a><br>Tel.: 32-2-555 62 45<br>LinkedIn: <a href="https://www.linkedin.com/in/gaurav-dube-b7566266/" target="_blank">https://www.linkedin.com/in/gaurav-dube-b7566266/</a></div></div></div></div></div></div>
</div></div>